 |
11 Diseases |  |
8 Trials |
|
8 Trials |  |
280 News |  |
| «1234 |
- | New P4 trial: Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist (clinicaltrials.gov) - Jun 26, 2013
P4, N=120, Completed, Sponsor: Universitair Ziekenhuis Brussel
- | Suprefact (buserelin acetate) / Sanofi
New P4 trial: Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles (clinicaltrials.gov) - Mar 20, 2013
P4, N=360, Recruiting, Sponsor: Andros Day Surgery Clinic
- | Trial completion: CAN-NCIC-PR7: Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer (clinicaltrials.gov) - Jan 9, 2013
P3, N=1386, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed
- docetaxel / Generic mfg.
Trial termination: Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Dec 16, 2012
P3, N=48, Terminated, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Completed --> Terminated; Poor accrual
- || Suprefact (buserelin acetate) / Sanofi, Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
New P3 trial: The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol (clinicaltrials.gov) - Jul 8, 2012
P3, N=200, Not yet recruiting, Sponsor: European Hospital
- | orteronel (TAK 700) / Takeda
Enrollment open: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Jun 9, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
Completed --> Terminated; Poor accrual Not yet recruiting --> Recruiting
- || orteronel (TAK 700) / Takeda
New P3 trial: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
- | Suprefact (buserelin acetate) / Sanofi
Enrollment open: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Jan 24, 2012
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Suprefact (buserelin acetate) / Sanofi
Trial completion, Surgery: SWOG-JPR3: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 8, 2012
P3, N=361, Completed, Sponsor: NCIC Clinical Trials Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Suprefact (buserelin acetate) / Sanofi
New P3 trial: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2011
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
- | Suprefact (buserelin acetate) / Sanofi
New P4 trial: Can Suprefact be given every forth month instead of third month with the same effect on castration levels. (EUDRACT) - Oct 10, 2011
P4, N=200, Ongoing, Sponsor: Urologkliniken US